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Moving towards a standards-based
methodological quality assessment scheme for
clinical research
It is evident from the increasing amount of published
literature regarding bias in epidemiology that the quality
of research has the potential to impact study results.1
The impact of methodological safeguards on study
results may vary according to the research context
and study design, and a comprehensive evidence base
suggests that consideration of such safeguards imple-
mented within a study is required to determine the
reliability of research findings.2 Assessment of the imple-
mentation of individual study safeguards is achieved
using a methodological quality assessment tool, the
interpretation of which is called a risk of bias judgment.
Although most quality assessment tools include mostly
bias safeguards, some may erroneously include report-
ing items not related to bias but this relates back to
researcher expertise and does not imply that reporting
checklists and quality assessment tools are the
same thing.
Over the last decade, many proposals have been laid
down for tools to assess study quality. Each of these tools
list a series of safeguards often grouped into many
different domains or subdomains of bias depending
on medical discipline and study design. There are there-
fore many tools available containing very different clas-
sifications of methodological safeguards.3 In addition,
frameworks that exist to create quality tools have led to
the proliferation of many tools rather than unifying the
duplication in this field.4 The result is that there is no
universally accepted single classification of quality safe-
guards across study designs.
Currently, quality assessment is interpreted either by
enumeration of safeguard items or by making judge-
ments based on domains or subdomains of bias items. In
an article soon to be published in this journal,5 a new
approach has been proposed that moves towards a
methodological standard-to-be-fulfilled scheme. The
bias safeguards are classified into methodological stand-
ards and the scale is called the MethodologicAl STand-
ards for Epidemiological Research (MASTER) scale.5 The
position taken is that it is the methodological standards
that these safeguards aim to fulfil, therefore these should
be a more meaningful system of subdomains for the
safeguards. The traditional approach, on the other hand,
simply classifies safeguards into convenient groups, and
therefore fulfilment of a domain/subdomain does not
necessarily link to deficiencies in a methodological stan-
dard and thus it does not mean a significant problem has
been averted. Thus domain judgements or safeguards
when used alone to assess quality may contribute dif-
ferently to the overall weight given to a standard, which
may not be empirically justified.
In the process of development of the MASTER scale
(preliminary version), many constructs were examined
and seven methodological standards emerged5:
(1) Equal recruitment (mainly selection bias related
safeguards). This standard is met when study safe-
guards against distortions to results from proce-
dures used to select study participants or from
factors that influence participation in the study
are present.
(2) Equal retention (mainly selection bias related
safeguards). This standard is met when safe-
guards are present that prevents distortion of
the study population away from the target popu-
lation due to losses and related factors during
the study, including protection from loss to
follow-up, competing risks, protocol violations,
and contamination.
(3) Equal ascertainment (mainly information bias and
design related safeguards). This standard is met
when identification of the exposure or nonexpo-
sure is protected through safeguards. In addition,
the detection of the outcome event as the ‘effect’
that follows the causal exposure is also protected
and safeguards in these areas make up this stan-
dard.6 Obviously, with ‘hard-outcome’ events, like
death, or an overt stroke, the safeguard is already
met. Safeguards become important if the outcome
is more subjective (e.g., symptoms or improve-
ment). In this situation, safeguards such as objec-
tive criteria or blinding to ensure that the appraiser
is unaware of whether or not the person was
exposed become important.
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(4) Equal implementation (mainly information bias
related safeguards). Bias may creep in when one
group of study participants in a study (e.g., a
control group or a treatment group) gets more
care from investigators than another group. The
difference in care levels result in systematic differ-
ences between groups, making it difficult or impos-
sible to conclude that a drug or other intervention
caused an effect, as opposed to level of care.6 This
is different from ascertainment where there is a
different level of diligence in measurement of
exposure or outcome.
(5) Equal prognosis (mainly analytic bias, confounding,
and design-related safeguards). Here the safe-
guards aid to equalize prognostic susceptibility
in the groups under study in terms of developing
the outcome event that is the subsequent effect of
the exposure under study.6
(6) Sufficient analysis (mainly analytic bias related safe-
guards). Safeguards are needed against removal of
cases for analytic reasons, not considering interac-
tions, unit of analysis errors, violated assumptions,
multicollinearity, and misspecification errors.
(7) Temporal precedence (mainly design-related safe-
guards). To establish a causal relationship, the
cause must be shown to have preceded the effect.6
If the effect is an outcome such as death, the
temporal sequence is clear but in other cases
the sequence may not be easy to demonstrate
without the design itself acting as a safeguard.
This new scheme based on standards listed above will
be published soon in this journal and views from the
community of researchers on what methodological
aspects need to be considered further would be wel-
come. Furthur research is required to empirically support
this approach and perhaps this can then lead in the
future to a standards-based weighting scheme through
meta-epidemiological research. We invite researchers
to contribute to this discussion on methodological
standards in epidemiological research through sugges-
tions and feedback.
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